(Q24241453)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

1 reference

title

Regular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse events (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

0 references

Toby J Lasserson

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

15 April 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

Cochrane Database of Systematic Reviews

26 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

CD006924

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19370661%20AND%20SRC:MED&resulttype=core&format=json

Once-daily budesonide/formoterol in a single inhaler in adults with moderate persistent asthma

26 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Twelve-week, randomized, placebo-controlled, multicenter study of the efficacy and tolerability of budesonide and formoterol in one metered-dose inhaler compared with budesonide alone and formoterol alone in adolescents and adults with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

The effect of budesonide and formoterol in one pressurized metered-dose inhaler on patient-reported outcomes in adults with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Efficacy and safety of a new pressurised metered-dose inhaler formulation of budesonide/formoterol in children with asthma: a superiority and therapeutic equivalence study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Efficacy and safety of budesonide and formoterol in one pressurised metered-dose inhaler in adults and adolescents with moderate to severe asthma: a randomised clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

An economic evaluation of combination treatment with budesonide and formoterol in patients with mild-to-moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Asthma quality of life during 1 year of treatment with budesonide with or without formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Additive effects of inhaled formoterol and budesonide in reducing asthma exacerbations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Long-term safety and asthma control with budesonide/formoterol versus budesonide pressurized metered-dose inhaler in asthma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Development of an economic model to assess the cost effectiveness of asthma management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Tolerability of a high dose of budesonide/formoterol in a single inhaler in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Budesonide/formoterol and formoterol provide similar rapid relief in patients with acute asthma showing refractoriness to salbutamol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

The effect of adjustable dosing with budesonide/formoterol on health-related quality of life and asthma control compared with fixed dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Adjustable maintenance dosing with budesonide/formoterol in a single inhaler provides effective asthma symptom control at a lower dose than fixed maintenance dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Addition of formoterol or montelukast to low-dose budesonide: an efficacy comparison in short- and long-term asthma control

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Beclometasone dipropionate/formoterol: in an HFA-propelled pressurised metered-dose inhaler.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Adjustable and fixed dosing with budesonide/ formoterol via a single inhaler in asthma patients: the ASSURE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Formoterol (Foradil) and medium-high doses of inhaled corticosteroids are more effective than high doses of corticosteroids in moderate-to-severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Formoterol Delivered via the Dry Powder Aerolizer® Inhaler Versus Albuterol MDI and Placebo in Mild-to-Moderate Asthma: A Randomized, Double-Blind, Double-Dummy Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Adjustable maintenance dosing with budesonide/formoterol or budesonide: double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Interaction revisited: the difference between two estimates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Beta-adrenergic receptors and their regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Systemic effects of salbutamol and salmeterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Lack of Evidence for Beta-2 Receptor Selectivity: a Study of Metaproterenol, Fenoterol, Isoproterenol, and Epinephrine in Patients with Asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

The cardio-toxicity of isoprenaline during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Long-acting beta2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Beyond the dogma: novel beta2-adrenoceptor signalling in the airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Prescribed fenoterol and death from asthma in New Zealand, 1981-7: a further case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Intracoronary injections of salbutamol demonstrate the presence of functional beta 2-adrenoceptors in the human heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Recovery from bronchoconstriction and bronchodilator tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Airway response to salbutamol: effect of regular salbutamol inhalations in normal, atopic, and asthmatic subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Inhaled beta 2-adrenoceptor agonists in asthma: help or hindrance?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Further observations on the cardiotoxicity of isoprenaline during hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Addition of inhaled long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Observations on recent increase in mortality from asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

Regular treatment with long acting beta agonists versus daily regular treatment with short acting beta agonists in adults and children with stable asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

The extrapulmonary effects of increasing doses of formoterol in patients with asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Beta-adrenoceptors and the epithelial layer in airways

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Aerosolized terbutaline in asthmatics: development of subsensitivity with long-term administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Regular inhaled salbutamol and airway responsiveness to allergen

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

A comparison of the speeds of action of salmeterol and salbutamol in reversing methacholine-induced bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

A randomized, double-blind trial of the effect of anti-asthma treatment on lung function in children with asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

The role of intrinsic efficacy in determining response to a beta2-agonist in acute severe asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Has the change to beta-agonists combined with oral theophylline increased cases of fatal asthma?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Tolerance to beta-agonists during acute bronchoconstriction

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Hypokalemia from Beta2-Receptor Stimulation by Circulating Epinephrine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Budesonide/formoterol improves lung function compared with budesonide alone in children with asthma.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Therapeutic comparison of a new budesonide/formoterol pMDI with budesonide pMDI and budesonide/formoterol DPI in asthma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Cardiovascular side effects of inhaled salbutamol in hypoxic asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Case-control study of prescribed fenoterol and death from asthma in New Zealand, 1977-81

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

An inhaled glucocorticoid does not prevent tolerance to the bronchoprotective effect of a long-acting inhaled beta 2-agonist

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

The safety of long-acting beta-agonists among patients with asthma using inhaled corticosteroids: systematic review and metaanalysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Beta-agonist intrinsic efficacy: measurement and clinical significance

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Formoterol as needed with or without budesonide in patients with intermittent asthma and raised NO levels in exhaled air: A SOMA study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Maintenance plus reliever budesonide/formoterol compared with a higher maintenance dose of budesonide/formoterol plus formoterol as reliever in asthma: an efficacy and cost-effectiveness study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Bronchodilator response to albuterol after regular formoterol and effects of acute corticosteroid administration

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Current issues with beta2-adrenoceptor agonists: pharmacology and molecular and cellular mechanisms

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021

Interactions between corticosteroids and beta2-agonists

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006924.PUB2

7 January 2021